diverticulitis
‘Switchable’ smart gel may pave the way for next-gen drug delivery and sensing tech
Researchers have created the first multi-responsive gel built from ‘foldamers’ - a discovery that could lead to smart sensors, switchable catalysts and more
Bowel Research UK appoints Kathryn Pretzel-Shiels as CEO
Pretzel-Shiels was most recently Interim CEO at the charity
New study highlights global overuse of antibiotics for diverticulitis
Researchers warn that excessive antibiotic use in diverticulitis increases risk of antimicrobial resistance and unnecessary hospital admissions
University of Liverpool identifies new class of antibiotic in fight against AMR
The new antibiotic class targets two of the WHO’s ‘priority pathogens’
UK government’s AMR study highlights importance of appropriate antibiotic use
The UKHSA found that some bacteria are already becoming resistant to ceftazidime/avibactam
Naturally occurring peptide shows promise as potential psoriasis treatment
The approach could reduce disease severity with fewer side effects than conventional treatments
AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections
Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health
UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance
The new analysis found that RSV infections lead to 640,000 antibiotic prescriptions every year
KCL research could speed up discovery of new antibiotics in fight against AMR
According to WHO, AMR is designated as one of the top ten global public health threats facing humanity
MIT protein study could help accelerate development of new antibiotics
Histidine kinase is a crucial bacterial protein that regulates processes, including antibiotic resistance
GSK becomes first founding partner of global initiative tackling antimicrobial resistance
AMR could cause an estimated ten million deaths every year by 2050 unless action is taken
Study reveals third COVID-19 vaccine dose improves defence in vulnerable patients
Approximately 90% of patients who received a third dose developed significant levels of antibodies